about
A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.Endothelial cells: source, barrier, and target of defensive mediators.Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.Kidney, heart and brain: three organs targeted by ageing and glycation.Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: A case report.Loss of DGKε induces endothelial cell activation and death independently of complement activation.[Vancomycin poisoning successfully treated with intermittent hemodialysis: A case report].Renal Cortical Necrosis in Postpartum Hemorrhage: A Case Series.Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis.FDG PET/CT allowing detection and follow-up of tumor cell transplantation.Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles[Renal malakoplakia: an underestimate cause of renal failure]Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients[New scores in renal transplantation: How can we use them?]Long-term outcome after early cyclosporine withdrawal in kidney transplantation: ten years afterCollapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidneyIn Reply to 'Risk of Tranexamic Acid for Treatment of Postpartum Hemorrhage'
P50
Q33399198-3FA84672-6CF7-4E24-8CA1-09CD4EA05104Q33407898-CE8AD830-8144-4F5F-8DFB-FE60690FCD69Q38991026-AC771BBB-940B-4709-B869-A4EF45B63AA3Q39016179-944D5983-5DE1-43E4-BBB5-2F5B20F7B1DAQ39313610-732765D5-6D49-4363-99FF-19BA5737BFA9Q41045314-EA80A703-752B-4AAD-8B4B-05BC83F03451Q41700443-09F975D0-BC0E-4A69-97B4-AC65FFE03CF9Q49360314-D450DDDE-3E2F-4A8F-B708-864C38B1AE1CQ50731375-B89495D7-51EB-471B-B35E-3BA77BC55B62Q52653120-0C49D9A9-455F-41EE-8430-F26C62BC40E8Q52986602-828AF002-A91C-43D3-A0A2-60AEB6CB8C47Q59617540-DDD04577-8222-45D9-BDFD-607DF83CE934Q82713104-E56DEC60-2652-4CC7-8E85-4B0D78F6F0E4Q86335189-00BA781B-7BAC-42A2-B5F2-E519B6FC1DF2Q88229025-F7D6DB39-76C0-46DD-963A-D1D1F0E18EC8Q88322897-71950328-038D-46C8-8E1E-223E78B060BAQ88373441-2EA51964-93FE-4DD3-9A0A-B01F501D0CF8Q89185714-B22B58C0-B57A-4628-A918-BBB8662C22FE
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-7461-8298
@en
name
Marie Frimat
@ast
Marie Frimat
@en
Marie Frimat
@es
Marie Frimat
@nl
type
label
Marie Frimat
@ast
Marie Frimat
@en
Marie Frimat
@es
Marie Frimat
@nl
prefLabel
Marie Frimat
@ast
Marie Frimat
@en
Marie Frimat
@es
Marie Frimat
@nl
P106
P31
P496
0000-0002-7461-8298